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In Brief
Paz-Yaacov et al. show that several types
of cancer are accompanied by elevated
activity of RNA editing, a process that
changes the sequence of RNA from that
encoded in the genome. Similar to
genomic mutations, this mechanism
results in multiple changes of the genetic
information, which may be beneficial for
cancer progression.
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Genomic mutations in key genes are known to drive
tumorigenesis and have been the focus of much
attention in recent years. However, genetic content
also may change farther downstream. RNA editing
alters the mRNA sequence from its genomic blue-
print in a dynamic and flexible way. A few isolated
cases of editing alterations in cancer have been re-
ported previously. Here, we provide a transcrip-
tome-wide characterization of RNA editing across
hundreds of cancer samples from multiple cancer
tissues, and we show that A-to-I editing and the en-
zymes mediating this modification are significantly
altered, usually elevated, in most cancer types.
Increased editing activity is found to be associated
with patient survival. As is the case with somatic mu-
tations in DNA, most of these newly introduced RNA
mutations are likely passengers, but a fewmay serve
as drivers thatmay be novel candidates for therapeu-
tic and diagnostic purposes.INTRODUCTION
Cancer is driven by alterations of the genomic information,
mainly mutations in key genes that provide the cancerous cell
a selective advantage for clonal multiplication. However, muta-
tions in the DNA are not the only source for modifying the
genomic content. RNA editing, a site-specific modification, al-
ters themRNA sequence from its genomic blueprint. RNA editing
is catalyzed by the adenosine deaminase acting on RNA (ADAR)
family of enzymes (Bass, 2002; Nishikura, 2010; Savva et al.,
2012). This alteration results in dynamic RNA mutations,
changes in the mRNA transcripts, which could ultimately lead
to outcomes similar to those of genomic mutations. Unlike a
genomic mutation, RNA editing affects varying fractions of the
copies of the targeted transcript, leading to much higher flexi-
bility. Alteration of editing was associated with cancer in some
studies (Cenci et al., 2008; Chen et al., 2013; Han et al., 2014;
Hu et al., 2015; Maas et al., 2001; Paz et al., 2007; Qin et al.,
2014; Shoshan et al., 2015), but transcriptome-wide character-Cization of this modification across multiple cancer tissues has
not been reported so far.
Here we show, using global measurements of RNA editing
levels in hundreds of cancer samples, that adenosine to inosine
conversion (A-to-I editing) and the enzymes mediating this
modification are significantly altered in most cancer types
screened, resulting in a sizable global effect on the transcrip-
tome. In most tumor types, editing levels are elevated compared
to their matched normal tissues, with the strongest signal de-
tected in breast, thyroid, head and neck, and lung cancers.
Overall, the number of RNA nucleotides modified by editing
events in cancerous tissues is of the same order of magnitude
as the genomic DNA mutation load. While the vast majority of
editing events take place within Alu repeats (Athanasiadis
et al., 2004; Bazak et al., 2014a; Blow et al., 2004; Kim et al.,
2004; Levanon et al., 2004), we have found several non-Alu sites
in coding sequences that were altered significantly in cancer.
Our results suggest that editing may supplement genomic
DNA alterations as a means to drive tumorigenesis. We hypoth-
esize that classification of both DNA and RNA modifications is
beneficial to determining a patient’s profile and treatment. As
is the case with cancer-associated somatic mutations, most
RNA editing events are likely passengers and only a few may
serve as drivers in each patient. Identifying these driver RNA
editing sites may provide novel candidates for therapeutic and
diagnostic purposes.
A-to-I RNA editing, mediated by the ADAR family of enzymes,
is considered the most common RNA modification in mammals,
with millions of editing sites detected so far in human (Bazak
et al., 2014a). The majority of human editing sites lie in non-cod-
ing regions of the transcriptome, especially in Alu elements,
which are likely to form long double-stranded RNA (dsRNA)
structures, the optimal targets for ADARs (Lehmann and Bass,
1999). Deregulation of the RNA editing process in tumors, lead-
ing to an elevated level of modified RNA nucleotides, therefore
may be analogous to genomic mutations.
Inosines are interpreted by the ribosome as guanosines. Thus,
A-to-I editing of coding mRNAs by ADARs may lead to recoding,
i.e., translation of a protein with amino acids different from those
encoded in the genome. Recoding by RNA editing serves as a
mechanism for creating structurally and functionally different
isoforms of proteins from the same transcript. Hundreds of re-
coding sites have been identified in human (Bahn et al., 2012;ell Reports 13, 267–276, October 13, 2015 ª2015 The Authors 267
Li et al., 2009; Park et al., 2012; Peng et al., 2012; Ramaswami
and Li, 2014; Ramaswami et al., 2013; Zhang and Xiao, 2015),
but only a few dozen of them are conserved (Pinto et al., 2014;
Xu and Zhang, 2014). However, the vast majority of editing activ-
ity in the human cell occurs at editing sites that do not result in
recoding and reside in the primate-specific Alu elements. In a
recent study (Bazak et al., 2014a), we quantified the relative
ADAR activity in recoding sites and found that it consists of
less than 1% of the global editing activity, which is mostly Alu
editing. We therefore focus first on quantifying Alu editing in
order to explore the global editing pattern in cancer tissues, as
a means toward understanding the global differential editing in
tumors.
RESULTS
Altered Editing in Alu Sites in Cancer and Matched
Normal Tissues
We started by studying Alu editing as a proxy for estimating the
global editing activity in a tissue. Employing an Alu-specific
editing detection algorithm (see Experimental Procedures), we
systematically screened A-to-I RNA editing alteration in 712
matched normal and cancerous RNA sequencing (RNA-seq)
samples, originating from nine tissue types, using data from
The Cancer Genome Atlas (TCGA) collection (Collisson et al.,
2014; Davis et al., 2014; Cancer Genome Atlas Network,
2012a, 2012b; Cancer Genome Atlas Research Network,
2014a, 2014b). In six of the cancer types tested (all but
kidney, prostate, and liver), we identified an elevated Alu editing
activity in tumors compared to the matched normal tissues.
Both the number of edited sites detected and the Alu editing
index (AEI), representing the weighted average editing level
across all expressed Alu sequences, were significantly in-
creased (Figure 1A; Tables 1 and S1). There are typically
thousands more editing sites detected in cancer tissues
compared to their normal matched tissues. In comparison,
the total number of genomic mutations ranges between hun-
dreds and tens of thousands (Alexandrov et al., 2013). The
same trend was seen using the complementary hyper-editing
detection scheme (see Experimental Procedures and Fig-
ure 1C), specialized for identifying clusters of editing sites
that are overlooked by standard alignment methods (Tables
S1 and S2). As expected, the number of editing sites identified
in the hyper-editing analysis correlated well with the AEI in each
tissue (Figure 1D).
The accuracy of editing prediction is usually estimated by the
ratio of A-to-G mismatches to the control mismatch (the most
frequent mismatch identified excluding A-to-G), which repre-
sents the noise level. Both theAlu and the hyper-editing analyses
showed a high signal-to-noise ratio (Figures 2A and 2C). In addi-
tion, one could observe the familiar ADAR motif signature for the
A-to-G sites, but a random-like pattern in the control (Figures 2B
and 2D). The fraction of detected sites that overlaps knownSNPs
and the distribution of sites between the read and transcript
strands (Figure S1) also support the notion that the A-to-G mis-
matches are mainly due to A-to-I editing. Taken together, these
results attest to the A-to-I editing origin of the observed A-to-G
mismatches.268 Cell Reports 13, 267–276, October 13, 2015 ª2015 The AuthorsADAR Expression Is Altered in Matched Normal and
Tumor Tissues
Themost obvious explanation for altered editing levels is amodi-
fied expression level of the ADAR enzymes. Indeed, the differen-
tial editing correlated well with the differential expression of
ADARs in the TCGA tissue collection (Figure 1B; Table S3).
ADAR1 levels were elevated in cancer for most tissues tested,
except for colon and kidney for which, consistently, no elevation
of editing was observed. On the other hand, expression of
ADAR2, which is much less abundant in the tissues studied,
showed a more complex pattern, consistent with the notion
that ADAR1 is the main enzymemediating Alu editing (Figure 1B;
Table S3.
AEI Is Associated with Survival Rate in Head and Neck,
Liver, and Breast Cancers
Importantly, editing alterations seem to be in association with
clinical results. Kaplan-Meier curves were generated for all tis-
sues, exhibiting that AEI (but not ADAR levels) could be used
to classify patients for survival rate in liver cancer (Figure 3A),
head and neck cancer (Figure 3B), and, to a lesser but significant
extent, breast cancer (Figure S2A). Interestingly, the effect in liver
cancer was gender dependent (Figure 3C): while the normal in-
dex level was similar in both genders, in the tumors males ex-
pressed high index values while females showed lower index
values. Our dataset size did not allow us to examine whether
AEI could be used to classify patients within genders. ADAR1
expression provided only a partial explanation for the gender dif-
ferences (Figure 3D). Hepatocellular carcinoma is known to be
gender biased, with females showing a longer survival rate
(Buch et al., 2008; Dohmen et al., 2003). Elevated editing in
AZIN1 recently was reported in hepatocellular carcinoma result-
ing in an oncogenic activity (Chen et al., 2013). In our limited set
of data, we did observe a significant alteration of editing in the
AZIN1 recoding site, but no correlation to the survival rate
(Figure S2B).
Altered Editing in Recoding Sites
While most editing takes place in Alu repeats (Bazak et al.,
2014a; Ramaswami and Li, 2014), the sites located in coding re-
gions are more likely to have a functional role. Recently, elevated
editing in AZIN1 recoding site was reported in hepatocellular car-
cinoma resulting in an oncogenic activity (Chen et al., 2013).
Here we extend this analysis and search systematically for
similar cases of a significant alteration of editing in recoding
sites, resulting in dozens of additional candidate drivers.
We looked at all such sites documented in the RADAR data-
base (Ramaswami and Li, 2014) and added all sites identified
in our hyper-editing analysis. Focusing on sites in coding se-
quences and filtering out synonymous Alu sites, SNPs, and
immunoglobulin sites resulted in a list of 9,484 sites (see Exper-
imental Procedures).We looked for sites that exhibited statisti-
cally significant and sizable (>5% in absolute terms) difference
in editing level between normal and tumor samples. Sixty such
sites were identified in at least one cancer type (Table S4; Fig-
ure 4A). Note that, typically, the coverage provided by RNA-
seq does not allow for effective and accurate quantification of
editing levels, and thus the full scope of modified recoding sites
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Figure 1. A-to-I RNA Editing Alteration in Cancer Versus Normal Tissues
(A) Editing is globally elevated in cancer. The distribution of Alu editing index (AEI) values in matched cancer and normal tissues is shown. The p values are shown
(bottom) and were calculated using the one-sample Wilcoxon signed-rank test (for the index difference between matched samples) and FDR-corrected for the
nine tests performed.
(B) ADAR1 expression levels are elevated in cancer. ADAR1 and ADAR2 expression level distributions in the matched normal and tumor tissues are shown.
ADAR1 levels are about an order of magnitude higher than those of ADAR2 and are elevated in cancer for all tissues tested, except colon and kidney, for which,
consistently, low or no elevation of editing was observed. In most tissues, but not in HNSC and THCA, the ADAR level may fully account for the observed AEI
differences (Table S3).
(C) Hyper-editing screening of the TCGA data results in a higher number of editing sites in cancer tissues. Distributions of the number of sites detected by the
hyper-editing screen for normal and tumor samples again show a higher number found in cancer, for most tissues.
(D) Correlation between the numbers of editing sites identified in the hyper-editing analysis and the AEI in each tissue. Red and blue colors refer to tumor and
normal samples, respectively. Pearson and Spearman correlation p values are indicated. All sites that overlapped known SNPs were removed. The strong
correlation between the independent editing measurements methods demonstrate that the two detection schemes work consistently.
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Table 1. Editing Differences between Cancer and Normal Samples
Tissue Type
Detected Editing Sites AEI
p Value (Index Difference)Average Normal Average Tumor Average Normal Average Tumor
BLCA (n = 13) 14,680 20,901 0.377 0.475 3.1E03
BRCA (n = 95) 28,700 30,775 0.430 0.561 6.3E13
COAD (n = 18) 10,143 12,847 0.257 0.293 0.046
HNSC (n = 29) 9,344 16,024 0.266 0.440 2.2E08
KIRC (n = 62) 20,819 17,572 0.467 0.438 0.065
LIHC (n = 30) 13,587 20,619 0.631 0.663 0.24
LUAD (n = 36) 13,033 15,915 0.300 0.388 2.2E04
PRAD (n = 31) 22,966 24,083 0.426 0.425 0.84
THCA (n = 42) 22,012 26,325 0.422 0.595 5.7E09
The table presents, for editing sites in Alu sequences, the following: (1) the average number of detected editing sites identified in total, for normal and
tumor tissues, (2) AEI value for normal and cancer tissues, and (3) statistical significance using the one-sampleWilcoxon signed-rank test to look at the
distribution of AEI differences (AEI[tumor]  AEI[normal]) for the matched samples. FDR-corrected p values are presented. AEI, Alu editing index;
BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; HNSC, head and neck squamous cell carci-
noma; KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; PRAD, prostate adenocarcinoma;
THCA, thyroid carcinoma. See also Table S1.might be larger than described here. Of the 60 sites, 14 exhibited
consistent altered editing in at least three (of the nine) tissues.
Interestingly, only 13 of the 52 non-synonymous sites (25%)
were predicted to have a deleterious effect on the protein
function (see Experimental Procedures and Table S4), com-
pared to 53% deleterious events among all non-synonymous
sites in our list (p = 0.0001; Table S4). This further supports
the hypothesis of modified editing being a putative driver for
tumorigenesis.
Altered Editing of MicroRNA Targets within Alu
Elements
Many 30 UTRs harbor microRNA (miRNA) targets, some of which
reside within Alu sequences and might be modified by A-to-I
editing. Alteration of miRNA regulation has been shown to be
associated with cancer progression. We looked at all 222,778
editing sites within Alu repeats in 30 UTRs that modify an miRNA
target, and we applied the same procedure as was done for the
sites in coding sequences. This resulted in 3,689 sites in 503
genes that showed significantly altered complementary seed
sites (Table S5). Most of the sites, such as the targets at PPIA
and METTL7A, were altered in multiple tissues.
DISCUSSION
Cancer is a complex and diverse disease affected by a multitude
of genetic alterations in each patient. DNA mutations are re-
cruited by cancer and passed on to all daughter cells, thus all tu-
mor cells either have themutation or not. In contrast, RNA editing
levels span the whole range between 0% and 100%, and may
change with time and cell state. These dynamic and flexible fea-
tures of RNA editing may be utilized for the benefit of cancer
progress, with varying levels of editing at each cell, possibly de-
pending on tumor stage and genomic mutation background. We
showed here that, in most cancers, editing is significantly
elevated compared to thematched normal tissue. In a few cases,
we also showed low editing index to be correlated with better270 Cell Reports 13, 267–276, October 13, 2015 ª2015 The Authorssurvival. Although these changes mostly reflect Alu editing,
they might turn out functional in several ways.
First, Alu editing might be relevant as a probe for the global
editing activity. Note that direct detection of modified editing
levels in specific recoding sites using RNA-seq is challenging.
Typical coverage of a few dozen reads allows only for a rough
estimate of the editing level, masking much of the alterations
that might occur between different biological conditions. Thus,
while we report here 60 significantly modified recoding sites,
many more may be undetectable due to limited coverage.
Moreover, as is the case with DNA mutations, additional sites
might be seen in sub-populations, thus undetectable in the cur-
rent study. Alu editing level is a much more sensitive and robust
probe for the global editing machinery activity. Its elevation,
probably by activation of the editing enzymes, indicates that
the number of recoding sites and their editing levels may be
elevated as well.
Second, altered editing in non-codingAlu repeatsmay result in
a profound effect on the gene stability, partnering, interaction,
and localization (Prasanth et al., 2005; Vitali and Scadden,
2010; Zhang and Carmichael, 2001). For example, editing of an
Alu element was shown to downregulate the formation of circular
RNAs (Ivanov et al., 2015), which in turn may increase the level of
certain miRNAs, e.g., mir-7 that is implicated in many cancers
(Hansen et al., 2013). Furthermore, many thousands of miRNA
targets are located within Alu sequences (Liang and Landweber,
2007) or can be created due to editing (Borchert et al., 2009), and
we have specifically verified that they also are affected byAlu ed-
iting alteration. Many of these targets are within known cancer-
related genes and therapeutic targets such as DHFR and CTSB.
Finally, Alu editing recently was suggested to induce selective
editing in recoding sites up to several hundred bases apart
(Daniel et al., 2014). Thus, the major increase in Alu editing
may result in induced recoding events in coding sequences
located close to the Alu elements.
Taken together, the results presented here, as well as cur-
rent results by other groups (Fumagalli et al., 2015; Han et al.,
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Figure 2. Editing Detection Scheme Yields a Clean Signal
(A) Distribution of the number of A-to-Gmismatcheswithin clusters inAlu repeats, over specific samples, compared to control (same for the secondmost frequent
mismatch identified, G-to-A). The ratio of the number of control mismatches to that of A-to-G mismatches is an estimator of the noise level. Clearly, A-to-G
mismatches are vastly over-represented, attesting to them being due to A-to-I editing rather than sequencing or alignment errors, SNPs, mutations, and so forth,
and the noise level (estimated by the number of G-to-A mismatches) is rather low.
(B) ADAR-mediated editing is characterized by under-representation of G base in the nucleotide upstream to the edited site (1) and over-representation of G
base in +1 position from the edited site. The detected A-to-G sites, but not the control G-to-A mismatches, exhibit the familiar motif signature of A-to-I editing, as
expected.
(C) Number of unique editing sites detected when applying the hyper-editing detection approach. Similar to the results in Alu, A-to-Gmismatches are vastly over-
represented.
(D) The detected sites in the hyper-editing analysis also show the familiar ADARmotif signature of A-to-I editing, while the control sites do not (see also Figure S1).2015), demonstrate that, in addition to genomic mutations, re-
programming by RNA modifications is another source for tran-
scriptome diversification in cancerous tissues. These correlative
observations reflect ADAR1 overexpression in cancer, and it re-
mains an open question as to whether a few of the resulting RNA
mutations play a causative role in tumor progression. Future
work, including larger numbers of sample tissues and functional
assays, is required to explore this question.CRNA editing by adenosine deaminases is not the first reported
case of recruitment of deaminase proteins for the creation of
cancer mutations. Recently it was shown that APOBEC3B, a
cytidine deaminase protein, can increase the rate of tumor
genome evolution by introducing loads of C-to-U mutations
into the DNA of cancer cells (Burns et al., 2013; Nik-Zainal
et al., 2012). The amount of excess RNA editing events in cancer
seems to be much higher than that of the reported cases ofell Reports 13, 267–276, October 13, 2015 ª2015 The Authors 271
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Figure 3. Kaplan-Meier Analysis of AEI
(A and B) Kaplan-Meier analysis demonstrates AEI is a good prognostic predictor in liver hepatocellular carcinoma (A) and head and neck tumors (B).
(C and D) AEI (C) and ADAR1 expression (D) are gender dependent in liver cancer tissues. Differences in ADAR expression do not fully account for the gender
differences. Looking at each gender separately, a significant (opposite direction) effect is visible for both genders (all n = 30, female = 13, male = 16). The merged
data for both genders do not show a clear trend in the editing index. Normal and tumor samples are indicated in blue and red, respectively (see also Figure S2).
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AB C
Reduced Elevated
Figure 4. Pan-cancer Editing Alteration in Coding Sequences
(A) Each column represents one of the 356 patients, and each row one of the 60 sites that were significantly modified in at least one cancer type. The color in each
position represents the difference in editing level per site per patient (blue, elevated editing in tumor; red, reduced in tumor). For example, the editing levels of the
P4HTM site are reduced in most kidney tumors while elevated in most breast cancer samples. Patients are grouped by tissue type and the top is color-coded to
indicate the tissue.
(B) Enlarged view of the bottom-left corner of (A). All bladder cancer samples and six editing sites are presented.
(C) Boxplot presentation of the distributions of editing levels in the FLNA editing site, for normal and cancer samples in each of the nine tissue types.
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APOBEC3B. Actually, the number of additional RNA editing
events in cancerous tissue, the RNA mutations, is comparable
to the total number of somatic mutation events in the cancer’s
DNA. The heterogeneity introduced by this phenomenon, over-
looked so far, may be recruited by tumor cells to play a role in
cancer progression.
EXPERIMENTAL PROCEDURES
Detection of Editing in RNA-Seq Data
RNA-seq data were downloaded from TCGA collection (https://tcga-data.nci.
nih.gov/tcga/) for tissues containing RNA-seq for both normal and tumor
samples from the same patient. In total, 356 patients were analyzed (712
RNA-seq) for nine different cancer types as follows (number indicates the num-
ber of matched samples that were analyzed after passing quality test from each
tissue): bladder urothelial carcinoma (BLCA, 13 patients), breast invasive carci-
noma (BRCA, 95 patients), colon adenocarcinoma (COAD, 18 patients), head
and neck squamous cell carcinoma (HNSC, 29 patients), kidney renal clear
cell carcinoma (KIRC, 62 patients), liver hepatocellular carcinoma (LIHC, 30 pa-
tients), lung adenocarcinoma (LUAD, 36 patients), prostate adenocarcinoma
(PRAD, 31 patients), and thyroid carcinoma (THCA, 42 patients).
Sequence readswere alignedusingSTAR (Dobin et al., 2013) to hg19withpa-
rameters that accept only uniquely aligned reads (outFilterMultimapNmax = 1)
and limit the number of mismatches to 0.05 of the mapped length
(outFilterMismatchNoverLmax = 0.05). Then, three editing detection schemes
were applied, as described subsequently.
Detection of Editing in Alu Elements
Over 99% of all editing activity in humans takes place in Alu.We thus used the
Alu editing as a robust probe for the global editing activity. The magnitude of
the effect and the distinctive features of editing in Alu repeats (e.g., clusters
of sites) result in an extremely clean signal, with minimal false-positive rate
(Bazak et al., 2014a).
To quantify Alu editing, we followed the approach described previously (Ba-
zak et al., 2014b). We collected all mismatches between the aligned reads and
the reference genome that occur within Alu elements, discarding mismatches
in read positions with quality Phred score <30 and those located at sites re-
ported as genomic SNPs in dbSNP (SNP build 135) (Eisenberg et al., 2005).
We filtered out mismatches’ positions that might be explained by sequencing
errors, based on a probabilistic model assuming an a priori sequencing error
rate of 0.001 (corresponding to Phred score Q = 30). Benjamini-Hochbergmul-
tiple testing correction was applied (for all Alu adenosines) with a false discov-
ery rate (FDR) of 0.05, resulting in a list of putative reliable mismatches. We
then looked for Alu elements for which a single type of mismatch dominated,
i.e., Alu elements in which the number of mismatches of the most common
mismatch type was higher than the number of mismatches of all other types
combined (see Table S1). Virtually all such Alu elements were dominated by
A-to-G mismatches and thus considered to be edited (Figure 2; Figure S2).
Editing sites of the dominant type within these Alus were considered to be
editing sites. Editing sites that we detected showed the familiar ADAR
sequence preference (Figure 2B; Eggington et al., 2011), tended to be more
deeply covered than non-A-to-G sites, and the edited version was supported
by more reads. Detected sites were uniformly distributed across read posi-
tions and (when occurring within RefSeq transcripts) conformed to the ex-
pressed strand (Figure S1), supporting the validity of the detection scheme.
AEI
Comparing editing levels in specific Alu sites requires ultra-high coverage, as
virtually all adenosines within most Alu repeats are being edited to some
extent, mostly to a low degree (<1%) (Bazak et al., 2014a, 2014b). Sites that
happen to be detected in a specific sample are not necessarily stronger;
most of them are a random sample of a small random fraction of the weakly
edited sites. A more robust measure of the global editing level in a given sam-
ple is provided by the AEI. This index measures the averaged editing level
across all Alu adenosines, weighted by their expression. It may be quantified
by the ratio of the number of A-to-G mismatches (presumably due to inosines)274 Cell Reports 13, 267–276, October 13, 2015 ª2015 The Authorsto the total number of reads—nucleotides aligned to a genomic adenosine
within an Alu repeat (representing edited and non-edited transcript adeno-
sines). As previously described (Bazak et al., 2014b), this index averages
over millions of adenosines and is, therefore, rather robust to statistical noise.
Whenever segmental duplication data were available in TCGA, we verified that
the differences in the AEI were not accounted for by duplications in the
cancerous cells.
Hyper-editing in RNA-Seq Data
Traditionally, RNA editing is detected by comparing RNA sequences to their
source DNA and searching for high-confidence A-to-G mismatches. We
have shown recently that this approach misses many heavily edited reads
(Carmi et al., 2011), which differ so widely from the corresponding DNA to
the extent that standard schemes fail to align them properly. A newly devised
pipeline allows for picking up the contribution of these heavily edited reads
(Porath et al., 2014). In this approach, one transforms all As to Gs in both the
unmapped reads and the reference genome and re-aligns them. Here, too,
the sites we found showed the familiar ADAR sequence preference (Figure 2D),
tended not to overlap known SNPs (unlike detected sites of non-A-to-G type)
(Figure S1B), were uniformly distributed across read positions (data not
shown), and (when occurring within RefSeq transcripts) conformed to the ex-
pressed strand (Figure S1C). Also, the results were evenmore clean than those
observed with the AEI. We applied this pipeline to the TCGA dataset, resulting
in further support of the trend seen using the AEI.
A-to-I Editing Sites in Coding Sequence
To analyze editing in the coding sequences, we compiled a list of editing sites
to be tested for alteration in cancer. We took all sites documented in the
RADAR database (Ramaswami and Li, 2014) in coding regions (UCSC annota-
tion, 47,025 sites), supplemented by novel sites detected using the hyper-
editing scheme within coding sequence (8,299 sites). We then excluded
synonymous sites within Alu repeats, sites located in immunoglobulins (likely
to be due to somatic hyper-mutations) and known SNPs (dbSNP 135). We
did keep the following three sites: chr20, 36147572; chr5,156736808; and
chrX,153579950 in the BLCAP, CYFIP2, and FLNA sites, respectively, which
are known editing sites (Levanon et al., 2005). We further removed all sites
annotated by wAnnovar (Chang andWang, 2012) as residing in non-coding re-
gions, resulting in 9,484 sites. We then quantified the editing levels in these
sites using the REDItools script (Picardi and Pesole, 2013), trimming six bases
at both ends of the reads.
For each of the sites, differences in editing level between normal and cancer
tissues were evaluated using the c2 test followed by 5% FDR multiple-testing
correction. Finally, we discarded sites where the absolute difference in the
average editing level between normal and cancer samples was less than 5%.
Putative deleterious sites are defined as those sites for which at least two of
wAnnovar analysis tools indicate a deleterious outcome. We found 3,520 such
events among the 6,723 non-synonymous sites in our list.
ADAR Expression
The DESeq package (Anders and Huber, 2010) in R was used for differential
gene expression analysis on normal and tumor samples (using UCSC gene
annotation tables [Karolchik et al., 2003]). The number of reads aligned to
each gene was calculated using featureCounts (Liao et al., 2014) with the
same alignment used in the Alu-specific approach (detailed in Table S3).
Survival Analysis
Kaplan-Meier analysis was executed in R to identify differential survival rates of
patients, classified by their tumor’s editing index. Index values most signifi-
cantly separating between high- and low-survival groups were selected for
each tissue. Only patients with paired tumor and normal samples were
included in the analysis. The p values were corrected for multiple testing
over the nine cancer types considered, setting the FDR to 0.05.
miRNA Target Alterations in Alu within 30UTRs
We have downloaded the human miRNA seed sequences from miRbase, and
we compiled the list of perfect complementary matches to these seeds within
Alu repeats in 30 UTRs. We then looked for editing sites that modify these
targets, and we applied the same pipeline and filters as described for the sites
in coding sequences to detect differentially edited sites.
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